SCHEMBL10109490

SCHEMBL10109490

CC1(C)CC[C@H]2c3cc(O)ccc3C[C@@H](c3ccc(O)cc3)[C@H]2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SHBG P04278 4/20 0.41
ESR1 P03372 12/20 0.41
ESR2 Q92731 11/20 0.41
LMNA P02545 5/20 0.38
HSD17B10 Q99714 4/20 0.38
STS P08842 3/20 0.38
HIF1A Q16665 3/20 0.38
AKR1B10 O60218 2/20 0.38
CYP1A2 P05177 2/20 0.38
PGR P06401 2/20 0.38
SERPINA6 P08185 2/20 0.38
CYP3A4 P08684 2/20 0.38
AR P10275 2/20 0.38
MAPT P10636 2/20 0.38
AKR1B1 P15121 2/20 0.38
SLC6A4 P31645 2/20 0.38
SNCA P37840 2/20 0.38
HTR2B P41595 2/20 0.38
BLM P54132 2/20 0.38
PMP22 Q01453 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL317920 1.00 SHBG (0.41) SHBGESR1ESR2LMNAHSD17B10
SCHEMBL319613 0.91 SHBG (0.40) SHBGESR1ESR2LMNAHSD17B10
SCHEMBL10109486 0.91 SHBG (0.40) SHBGESR1ESR2LMNAHSD17B10
SCHEMBL10109104 0.81 LMNA (0.41) ESR1LMNAHSD17B10STSHIF1A
SCHEMBL318204 0.81 LMNA (0.41) ESR1LMNAHSD17B10STSHIF1A
SCHEMBL10109447 0.79 ESR1 (0.55) SHBGESR1ESR2
SCHEMBL10109456 0.79 ESR1 (0.55) SHBGESR1ESR2
SCHEMBL318438 0.79 ESR1 (0.55) SHBGESR1ESR2
SCHEMBL319643 0.79 ESR1 (0.55) SHBGESR1ESR2
SCHEMBL10109442 0.79 ESR1 (0.55) SHBGESR1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8093302-B2 Substituted tetralins as selective estrogen receptor-β agonists ELI LILLY AND COMPANY (US) 2012-01-10 US disclosed
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ELI LILLY AND COMPANY (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249075-A1 SUBSTITUTED TETRALINS AS SELECTIVE ESTROGEN RECEPTOR-BETA AGONISTS ESR2, ERLIN1, ESRRG SHBG 15/4885ESR1 6/4885ESR2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.